Exclusive details on Cybin's IND application with the FDA, a move that could make its CYB003 compound the first psilocybin analog to be evaluated in Phase 1/2a development.
Subscribe to:
Post Comments (Atom)
< + > CIO Podcast – Episode 122: C-Suite Executive Roles with Saad Chaudhry
For the 122nd episode of the CIO podcast hosted by Healthcare IT Today, we are joined by Saad Chaudhry, CEO at Evergreen Healthcare Partner...
No comments:
Post a Comment